Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

SIM0237 Phase I/II Clinical Study Data in Non-muscle-invasive Bladder Cancer Presented at the European Association of Urology Annual Congress 2026

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, SIM0237 (PD-L1/IL15v bispecific antibody), an innovative fusion protein independently developed by the Group, presented Phase I/II clinical study data for the treatment of Bacillus Calmette-Guérin ("**BCG**")-unresponsive high-risk non-muscle-invasive bladder cancer ("**NMIBC**") at the European Association of Urology Annual Congress 2026 (EAU 2026).

As of the data cut-off date (November 28, 2025), a total of 49 patients had received intravesical instillation of SIM0237 monotherapy. Among patients with carcinoma in situ (CIS) who had at least one post-baseline tumor assessment, 80% achieved the complete response (CR). Among patients with papillary-only disease, the 12-month disease-free survival (DFS) rate was 65.8%. Overall, the results demonstrate a promising clinical efficacy signal of SIM0237 in patients with BCG-unresponsive high-risk NMIBC.

In terms of safety, intravesical administration of SIM0237 demonstrated favorable safety and tolerability, and serum sample analysis showed no detectable systemic exposure to the drug.

ABOUT SIM0237

SIM0237 is a fusion protein independently developed based on the Group's proprietary protein engineering technology platform, consisting of an anti-PD-L1 monoclonal antibody and an IL-15/IL15R α sushi domain. By binding to PD-L1, SIM0237 blocks the PD-1/PD-L1 immune inhibitory pathway, while simultaneously activating the immune system through IL-15, thereby exerting antitumor effects through the dual synergistic mechanisms of relieving immune suppression and activating immune responses.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, March 17, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.